BIOXCEL THERAPEUTICS INC's ticker is BTAI and the CUSIP is 09075P105. A total of 96 filers reported holding BIOXCEL THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 1.24 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $54,524 | -74.0% | 21,551 | -31.5% | 0.00% | – |
| Q2 2023 | $209,497 | -37.5% | 31,456 | +75.1% | 0.00% | – |
| Q1 2023 | $335,190 | +11.6% | 17,963 | +28.5% | 0.00% | – |
| Q4 2022 | $300,290 | +79.8% | 13,980 | -1.1% | 0.00% | – |
| Q3 2022 | $167,000 | -9.7% | 14,130 | +0.6% | 0.00% | – |
| Q2 2022 | $185,000 | -38.9% | 14,041 | -3.2% | 0.00% | – |
| Q1 2022 | $303,000 | +9.8% | 14,500 | +6.8% | 0.00% | – |
| Q4 2021 | $276,000 | -32.7% | 13,574 | +0.5% | 0.00% | – |
| Q3 2021 | $410,000 | +13.6% | 13,511 | +8.6% | 0.00% | – |
| Q2 2021 | $361,000 | -32.8% | 12,443 | -0.1% | 0.00% | – |
| Q1 2021 | $537,000 | -76.2% | 12,450 | -74.5% | 0.00% | -100.0% |
| Q4 2020 | $2,254,000 | -12.4% | 48,751 | -17.9% | 0.00% | -50.0% |
| Q3 2020 | $2,574,000 | +1.2% | 59,380 | +23.8% | 0.00% | 0.0% |
| Q2 2020 | $2,543,000 | – | 47,982 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Knoll Capital Management, LLC | 60,000 | $151,800 | 0.16% |
| XTX Topco Ltd | 33,605 | $85,021 | 0.02% |
| Beacon Pointe Advisors, LLC | 301,735 | $763,390 | 0.01% |
| AllSquare Wealth Management LLC | 4,527 | $11,453 | 0.01% |
| Virtus ETF Advisers LLC | 4,646 | $11,754 | 0.01% |
| Y-Intercept (Hong Kong) Ltd | 27,553 | $69,709 | 0.01% |
| SeaCrest Wealth Management, LLC | 16,550 | $41,872 | 0.01% |
| Hennion & Walsh Asset Management, Inc. | 33,940 | $85,868 | 0.01% |
| Cutler Group LLC / CA | 4,000 | $50 | 0.01% |
| Capital Investment Advisory Services, LLC | 17,991 | $45,517 | 0.00% |